Publicaciones Seleccionadas

Identification of PLK1 as a therapeutic target in BRCA1-deficient cancers (2019)

In this work we developed a flow-cytometry-based co-culture screening technology for drug discovery, and we used to explore a public kinase inhibitor set.

Bioprospecting South American flora for synthetic lethal lead compounds (2020)

In this work we used our flow-cytometry-based co-culture screening technology to screen a collection of 50 plants species from South America in a wide dose-response scheme.

Screening of regulatory partners of ZEB1 to inhibit its pro-metastatic properties (2019)

In this work we performed In Silico screenings to identifty phosphor regulatory sites of the EMT factor ZEB1 and validated PKCα as a novel partner capable of modulating its premetastatic properties.

Repurposing of breast cancer transcriptomic signature for pan-cancer applications (2020)

In this work we perform studies of correlations of drug sensitivity of a cell line database with transcriptomic classes of cancer cells derived from a commercial breast cancer signature.

Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency

In this collaborative effort with GSK, Cellzome, UCLA, The Leloir Institute, and the National University of Córdobawe performed a synthetic lethality screen with natural products from Argentina, which allowed us to identify dCK as a novel target in BRCA2-deficient cancers.

Identification of PLK1 as a therapeutic target in BRCA1-deficient cancers (2019)

In this work we developed a flow-cytometry-based co-culture screening technology for drug discovery, and we used to explore a public kinase inhibitor set.

Bioprospecting South American flora for synthetic lethal lead compounds (2020)

In this work we used our flow-cytometry-based co-culture screening technology to screen a collection of 50 plants species from South America in a wide dose-response scheme.

Screening of regulatory partners of ZEB1 to inhibit its pro-metastatic properties (2019)

In this work we performed In Silico screenings to identifty phosphor regulatory sites of the EMT factor ZEB1 and validated PKCα as a novel partner capable of modulating its premetastatic properties.

Repurposing of breast cancer transcriptomic signature for pan-cancer applications (2020)

In this work we perform studies of correlations of drug sensitivity of a cell line database with transcriptomic classes of cancer cells derived from a commercial breast cancer signature.

Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency

In this collaborative effort with GSK, Cellzome, UCLA, The Leloir Institute, and the National University of Córdobawe performed a synthetic lethality screen with natural products from Argentina, which allowed us to identify dCK as a novel target in BRCA2-deficient cancers.

Publicaciones